Finance

Beta
Lists
KRRO:NASDAQ
Korro Bio Inc
$13.20
+3.90%
(+0.49) 1D
$13.20
0.00% (0.00)
After hours
Closed: Jun 29, 3:56:52 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KRRO...
Open
$12.65
High
$13.40
Low
$12.31
Mkt. cap
189.22M
Avg. vol.
224.56K
Volume
118.38K
52-wk high
$55.89
52-wk low
$5.20
EPS
-$11.67
Beta
3.01
Shares outstanding
14.42M
No. of employees
49
Open
$12.65
High
$13.40
Low
$12.31
Mkt. cap
189.22M
Avg. vol.
224.56K
Volume
118.38K
52-wk high
$55.89
52-wk low
$5.20
EPS
-$11.67
Beta
3.01
Shares outstanding
14.42M
No. of employees
49
News stories
From sources across the web
About Korro Bio Inc
CEO-
Employees49
Founded2014
Headquarters-
SectorBiotechnology
Analyst ratings
Based on 8 analysts giving stock ratings to KRRO in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for KRRO in the last 3 months.
Highest
Current $13.20
$30.00 (+127.36%)
Average
$19.00 (+43.99%)
Lowest
$8.00 (-39.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
LifeSci Capital
Buy
Initiated
$21.00
+59.2%
05/30/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$30.00
+127.4%
05/28/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Maintained
$15.00
+13.7%
05/26/2026
Yigal Nochomovitz
Citi
Buy
Initiated
$21.00
+59.2%
05/18/2026
Myles Minter
William Blair
Buy
Maintained
-
-
05/18/2026
Catherine Novack
JonesTrading
Buy
Upgraded
$23.00
+74.3%
05/08/2026
Luca Issi
RBC Capital
Hold
Maintained
$8.00
-39.4%
05/08/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$15.00
+13.7%
05/07/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$22.00
+66.7%
03/13/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
$22.00
+66.7%
03/12/2026
William Maughan
Clear Street
Buy
Maintained
$18.00
+36.4%
03/13/2026
Ryan Deschner
Raymond James
Buy
Upgraded
$23.00
+74.3%
03/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.46M
1.09M
1.29M
-
Cost of goods sold
18.36M
11.26M
8.60M
11.53M
Cost of revenue
18.36M
11.26M
8.60M
11.53M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.30M
9.06M
8.58M
8.91M
Operating expense
10.30M
9.06M
8.58M
8.91M
Total operating expenses
28.66M
20.33M
17.18M
20.44M
Operating income
-27.20M
-19.24M
-15.88M
-20.44M
Other non operating income
1.43M
1.18M
990.00K
-
EBT including unusual items
-25.77M
-18.06M
-49.41M
-19.53M
EBT excluding unusual items
-25.77M
-18.06M
-14.89M
-19.53M
Income tax expense
1.00K
-
636.00K
95.00K
Effective tax rate
-
-
-1.29%
-0.49%
Other operating expenses
-
-
-
-
Net income
-25.77M
-18.06M
-50.04M
-19.62M
Net profit margin
-1,765.07%
-1,656.97%
-3,873.22%
-
Earnings per share
-2.74
-1.92
-1.65
-1.69
Interest and investment income
-
-
-
906.00K
Interest expense
-
-
-
-
Net interest expenses
-
-
-
906.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.98M
-18.06M
-15.23M
-20.06M
Gain or loss from assets sale
81.00K
-
-18.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more